Lyka Labs Limited Market Cap ($29.17 Million)
Market Cap & Net Worth: Lyka Labs Limited (LYKALABS)
Lyka Labs Limited market cap. Lyka Labs Limited (NSE:LYKALABS) has a market capitalization of $29.17 Million (Rs2.70 Billion) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #23673 globally and #1306 in its home market, demonstrating a -5.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyka Labs Limited's stock price Rs75.57 by its total outstanding shares 35690000 (35.69 Million). Also see LYKALABS cash generation efficiency for how efficiently the company converts equity into cash flow.
Lyka Labs Limited Market Cap History (2015–2026)
Lyka Labs Limited market cap history from 2015 to 2026. Data shows change from $49.50 Million to $29.17 Million (-1.71% CAGR). Check Lyka Labs Limited (LYKALABS) share price today for real-time trading data and today's change.
Lyka Labs Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyka Labs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LYKALABS shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Lyka Labs Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.37x
Lyka Labs Limited's market cap is 0.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $20.57 Million | $1.28 Billion | $36.87 Million | 0.02x | 0.56x |
| 2017 | $24.86 Million | $993.80 Million | -$55.38 Million | 0.03x | N/A |
| 2018 | $11.71 Million | $563.60 Million | -$172.75 Million | 0.02x | N/A |
| 2019 | $7.57 Million | $642.38 Million | -$55.50 Million | 0.01x | N/A |
| 2020 | $11.97 Million | $554.08 Million | -$605.41 Million | 0.02x | N/A |
| 2021 | $85.49 Million | $671.07 Million | -$115.55 Million | 0.13x | N/A |
| 2022 | $50.06 Million | $1.84 Billion | $390.00 Million | 0.03x | 0.13x |
| 2023 | $47.76 Million | $916.90 Million | -$132.12 Million | 0.05x | N/A |
| 2024 | $60.91 Million | $1.05 Billion | -$24.89 Million | 0.06x | N/A |
| 2025 | $29.29 Million | $1.41 Billion | $80.12 Million | 0.02x | 0.37x |
Competitor Companies of LYKALABS by Market Capitalization
Companies near Lyka Labs Limited in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Lyka Labs Limited for a full breakdown of the balance sheet.
Key companies related to Lyka Labs Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Lyka Labs Limited (2015–2026)
Market capitalization of Lyka Labs Limited from 2015 to today. Between 2015 and today, Lyka Labs Limited's market cap moved from $49.50 Million to $ 29.17 Million, with a yearly change of -1.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs29.17 Million | -0.42% |
| 2025 | Rs29.29 Million | -51.91% |
| 2024 | Rs60.91 Million | +27.53% |
| 2023 | Rs47.76 Million | -4.59% |
| 2022 | Rs50.06 Million | -41.44% |
| 2021 | Rs85.49 Million | +614.52% |
| 2020 | Rs11.97 Million | +58.16% |
| 2019 | Rs7.57 Million | -35.42% |
| 2018 | Rs11.71 Million | -52.87% |
| 2017 | Rs24.86 Million | +20.83% |
| 2016 | Rs20.57 Million | -58.44% |
| 2015 | Rs49.50 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Lyka Labs Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.17 Million USD |
| MoneyControl | $29.17 Million USD |
| MarketWatch | $29.17 Million USD |
| marketcap.company | $29.17 Million USD |
| Reuters | $29.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more